He was speaking during the launch of 'Compact XL, a compact diagnostics machine by MyLab Discovery Solutions, that will automate lab processes from sample handling to preparing RT-PCR tubes
Vaccine maker Serum Institute of India (SII) is hoping to develop a COVID-19 vaccine by the year-end as it is focusing on a “good and safe” product and is not in a “rush”, the company’s CEO Adar Poonawalla said.
He was speaking during the launch of ‘Compact XL, a compact diagnostics machine by MyLab Discovery Solutions, that will automate lab processes from sample handling to preparing RT-PCR tubes.
Replying to a question about the development of the COVID-19 vaccine, Poonawalla said that by the end of 2020, the SII is hoping to have a vaccine.
“End of the year, we are hoping to have a vaccine. So we will discuss once of the phase three trials for the product come about. Recently, there was news about another vaccine candidate which was being rushed. We do not want to rush anything. We want to emphasis on safety and efficacy… and once we are confident of good and safe vaccine, we will announce but that is still six months away from now,” said Adar.
He further said that till the vaccine comes, testing is the key and that is why SII has invested in MyLabs.
“If you test, isolate and segregate, we can manage the situation till the good cure or vaccine comes around,” said Adar.
SII has invested over Rs 100 crore in MyLabs, a Pune-based molecular diagnostics firm.
Poonawalla lamented that India is not testing enough and added that Indian test manufacturers including MyLabs are picking up the production capacity.
“There is a fear that what will happen if the number of positive patients increases. I would like to say that there is no harm if the number increases as it will help us detect people,” he added.
Poonawalla also sought permission to allow export of the test kits.
“We have enough capacity in manufacturing testing kits. MyLab can produce 2 million kits per week and there is no that much demand in India so allow us to export and we have enough buffer stock for India readily available if there is more outbreak,” he said adding they are waiting for the government’s blessings.
Source - ExpressPharma
Oxford R21/Matrix-M™ malaria vaccine receives WHO recommendation for use paving the way for global roll-out
Adar Poonawalla awarded 'Business Leader of the Year' 2023 by the International Advertising Association (IAA) India Chapter
Cyrus Poonawalla Group appoints Keki Mistry as Strategic Advisor to all the Financial Services Ventures led by Adar Poonawalla
R21/Matrix-M™ malaria vaccine developed by University of Oxford receives regulatory clearance for use in Ghana
Department of Biotechnology announces the scientific completion of India's first qHPV vaccine ‘CERVAVAC’
Adar Poonawalla, CEO, Serum Institute of India, receives the award for the Outstanding Business Leader of the Year
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia
Serum Institute Of India sends out Covishield vaccine - Consignment of Covishield Vaccine arrived in Delhi, Chennai, Kolkata, Guwahati, Shillong, Ahmedabad, Hydrabad, Vijayawada, Bhubaneswar, Patna, Bengaluru, Lucknow, Chandigarh
Serum Institute of India launches India’s first fully indigenously developed pneumococcal vaccine, 'PNEUMOSIL'
Oxford COVID-19 vaccine: Serum Institute likely to submit final Covishield trial data within 10 days
SII’s Adar Poonawalla on Covid vaccine, pricing and rollout at Hindustan Times Leadership Summit 2020
COVISHIELD Completes Enrolment of Phase III clinical trials under partnership of ICMR and Serum Institute of India
Government Secures Vaccine Supplies For Half Of The Indian Population From Serum Institute And Novavax
IAVI, Merck, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
Serum Institute Of India Takes A Multipronged Approach In Quest To Produce World’s First Covid-19 Vaccines
Serum Institute of India to produce up to an additional 100 million covid 19 vaccine doses for india and low and midle income countries in 2021
Adar Poonawalla CEO of Serum Institute of India, the world’s largest vaccine manufacturer, explains the timing, challenges & cost of vaccinating the world against COVID-19
Serum Institute looking for a $1 billion shot to fight covid, talks on with Blackstone, KKR and others
Serum Institute of India Says Covid Vaccine Likely to Be Ready by End of 2020, Final Pricing in 2 Months
Serum institute of india to produce up to 100 million covid-19 vaccine doses for india and low-and middle-income countries as early as 2021
50% of our Covid vaccines will be for India, people won't have to buy them, govts will pay: Adar Poonawalla
AstraZeneca vaccine's success in early human trials, Will Begin AstraZeneca Vaccine Trial in India After Applying for Licence Next Week, Says Serum Institute
Serum Institute of India CEO: ‘We plan to make millions of doses of Covid vaccine over three months’:’
New supply agreement between UNICEF and Serum Institute of India makes pneumococcal conjugate vaccine available at US$2.00 per dose, a 43 % reduction from the Gavi price at the start of the Advance Market Commitment
Serum Institute confident of manufacturing Covid vaccine’s 100 million doses if trials establish efficacy
Serum Institute’s Journey To Success | ET NOW Covid-19 vaccine possible by Q2 of 2022: Adar Poonawalla
Adar Poonawalla discusses Serum Institute's progress in the global battle against COVID-19 with Shereen Bhan, CNBC-TV18
Adar Poonawalla talks with Aabha Bakaya about the success story of Serum Institute of India. Tune in to know all about the journey of the company.
Bill Gates confers Indian Council of Medical Research "Lifetime Achievement Medal" on Dr. Cyrus Poonawalla
Dr. Cyrus Poonawalla conferred with 'Lifetime Achievement Award’ by the Asian Business Leadership Forum
Dr. Cyrus Poonawalla conferred with the prestigious honorary degree by the University of Oxford, U.K.